PUBLISHER: Polaris Market Research | PRODUCT CODE: 1625427
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1625427
CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034
The global CAR-T cell therapy market size is expected to reach USD 188.84 billion by 2034, according to a new study by Polaris Market Research. The report "CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen [CD19/CD22, BCMA (B-Cell Maturation Antigen), and Others], and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Chimeric Antigen Receptor T-cell (CAR-T) therapy represents an advancement in cancer treatment, transforming immuno-oncology. The therapy offers personalized and highly effective treatment options for certain cancers, particularly hematological malignancies, by engineering a patient's T-cells to express synthetic receptors that target specific cancer antigens. The global CAR-T cell therapy market has witnessed exponential growth over the last decade, driven by rapid advancements in biotechnology, increasing approval rates of CAR-T therapies, and rising demand for innovative cancer treatments.
The increasing prevalence of cancer globally, coupled with a growing preference for precision medicine, has fueled demand for advanced treatment modalities such as CAR-T cell therapy. Moreover, supportive regulatory frameworks and rapid approval pathways have accelerated the availability of CAR-T therapies. Government and private investments in research further propel the CAR-T cell therapy market expansion.
The development of next-generation CAR-T therapies, including multi-target CAR-T cells and armored CAR-T cells, is driving the CAR-T cell therapy market growth. Multi-target CAR-T cells are engineered to recognize multiple antigens, addressing issues such as tumor heterogeneity and antigen escape, which limit the efficacy of traditional CAR-T treatments. Armored CAR-T cells are designed to overcome the immunosuppressive tumor microenvironment by secreting cytokines or other molecules to enhance anti-tumor activity.
The application of CAR-T therapy is expanding beyond oncology. Researchers are exploring its potential in treating autoimmune diseases such as lupus and multiple sclerosis and infectious diseases, including HIV. These novel applications are estimated to significantly broaden the market scope and impact.
CAR-T Cell Therapy Market Report Highlights
In terms of indication, the follicular lymphoma (FL) segment is expected to grow at the fastest pace, with a CAGR of 43.2% during the forecast period due to the rising incidence of refractory and high-risk cancer cases.
Based on target antigen, the CD19/CD22 antigen segment, valued at USD 6,258.5 billion in 2024, held the largest market share owing to its established role in treating B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).
In the global market, the North America CAR-T cell therapy market held a 47.16% market share in 2024 due to the presence of advanced healthcare infrastructure, significant research and development investments, and a high prevalence of hematologic malignancies.
The Europe CAR-T cell therapy market is expected to witness a CAGR of 33.2% during the forecast period due to increased focus on expanding access to advanced therapies, coupled with the rising prevalence of relapsed or refractory hematologic cancers.
A few of the global key market players are Bluebird Bio; Celgene Corporation; Gilead Sciences; Cellectis; Servier Laboratories; Pfizer Inc.; Merck; Amgen; Intellia Therapeutics; Novartis; Caribou Biosciences; Celyad; Bellicum Pharmaceuticals, Inc.; Noile-Immune Biotech; Nanjing Legend Biotechnology Co., Ltd.; Johnson & Johnson; and Sangamo Therapeutics, Inc.
Polaris Market Research has segmented the CAR-T cell therapy market report on the basis of indication, antigen, and region:
By Indication Outlook (Revenue, USD Billion, 2020-2034)
- DLBCL (Diffuse large B-cell lymphoma)
- ALL (Acute Lymphoblastic Leukemia)
- CLL (Chronic Lymphocytic Leukemia)
- MM (Multiple Myeloma)
- FL (Follicular Lymphoma)
- Mastozytosis
- Myeloid Fibrosis
- MLL (Mixed Lineage Leukemia)
- Thymic Cancer
- Glioblastoma
- AML (Acute Myeloid Leukemia)
- Other
By Target Antigen Outlook (Revenue, USD Billion, 2020-2034)
- CD19/CD22
- BCMA (B-Cell Maturation Antigen)
- Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
Chapter 1. Introduction
- 1.1 Report Description
- 1.1.1 Objectives of the Study
- 1.1.2 Market Scope
- 1.2 Assumptions
- 1.3 Stakeholders
- 1.4 List of Abbreviations
Chapter 2. Executive Summary
- 2.1 Market Highlights
Chapter 3. Research Methodology
- 3.1 Overview
- 3.1.1 Data Mining
- 3.2 Data Sources
- 3.2.1 Primary Sources
- 3.2.2 Secondary Sources
Chapter 4. CAR-T Cell Therapy Market Insights
- 4.1 CAR-T Cell Therapy Market Dynamics
- 4.1.1 Drivers and Opportunities
- 4.1.1.1 Promising growth in leukemia segment for DLBCL and Multiple Myeloma coupled with launches
- 4.1.1.2 Potential applications in solid tumor
- 4.1.2 Restraints and Challenges
- 4.1.2.1 Patient Relapse
- 4.1.2.2 Manufacturing and logistics challenges
- 4.1.2.3 Economic model/reimbursement/scaling
- 4.1.1 Drivers and Opportunities
- 4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers (High)
- 4.2.2 Threats of New Entrants: (High)
- 4.2.3 Bargaining Power of Buyers (Low)
- 4.2.4 Threat of Substitute (Low)
- 4.2.5 Rivalry among existing firms (High)
- 4.3 PEST Analysis
- 4.4 Timeline of CAR-T Cell Therapy Development
- 4.5 CAR-T Cell Manufacturing Outlook
- 4.6 Side-effects of CAR-T Cell
- 4.7 Antigens targeting solid tumors
- 4.8 Clinical trials Landscape for CAR-T
- 4.9 Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
- 4.10 New Innovations in CAR-T therapies
- 4.10.1 "Off-the-shelf" CAR-T or allogenic CAR-T
- 4.10.2 Development of Dual CAR-T
- 4.10.3 Development of Non-viral transcription technologies
- 4.10.4 The advent of TIL as well as TC R therapies
- 4.10.4.1 TCR (T-cell receptor)
- 4.10.4.2 TIL (Tumor-Infiltrating Lymphocytes)
- 4.11 CAR-T Cell Therapy Market - Covid Impact Analysis
- 4.12 Customization - CAR-T Cell Market
Chapter 5. CAR-T Cell Therapy Market Assessment by Indication
- 5.1 Introduction
- 5.2 DLBCL
- 5.3 ALL
- 5.4 CLL
- 5.5 MM
- 5.6 FL
- 5.7 Mastozytosis
- 5.8 Myeloid Fibrosis
- 5.9 MLL
- 5.10 Thymic Cancer
- 5.11 Glioblastoma
- 5.12 AML
- 5.13 Other Indications
Chapter 6. Global CAR-T Cell Therapy Market, by Target Antigen
- 6.1 Introduction
- 6.2 CD19/CD22
- 6.3 BCMA
- 6.4 Others
Chapter 7. CAR-T Cell Therapy Market Assessment by Geography
- 7.1 Introduction
- 7.2 CAR-T Cell Therapy Market - North America
- 7.2.1 CAR-T Cell Therapy Market - U.S.
- 7.2.2 CAR-T Cell Therapy Market - Canada
- 7.3 CAR-T Cell Therapy Market - Europe
- 7.3.1 CAR-T Cell Therapy Market - Germany
- 7.3.2 CAR-T Cell Therapy Market - UK
- 7.3.3 CAR-T Cell Therapy Market - France
- 7.3.4 CAR-T Cell Therapy Market - Italy
- 7.3.5 CAR-T Cell Therapy Market - Spain
- 7.3.6 CAR-T Cell Therapy Market - Netherlands
- 7.3.7 CAR-T Cell Therapy Market - Austria
- 7.4 CAR-T Cell Therapy Market - Asia Pacific
- 7.4.1 CAR-T Cell Therapy Market - China
- 7.4.2 CAR-T Cell Therapy Market - India
- 7.4.3 CAR-T Cell Therapy Market - Japan
- 7.4.4 CAR-T Cell Therapy Market - South Korea
- 7.4.5 CAR-T Cell Therapy Market - Australia
- 7.5 CAR-T Cell Therapy Market - Latin America
- 7.5.1 CAR-T Cell Therapy Market - Brazil
- 7.5.2 CAR-T Cell Therapy Market - Mexico
- 7.6 CAR-T Cell Therapy Market - Middle East & Africa
- 7.6.1 CAR-T Cell Therapy Market - Saudi Arabia
- 7.6.2 CAR-T Cell Therapy Market - UAE
Chapter 8. Competitive Landscape
- 8.1 Product Launch and Acquisition Are the Best Adopted Strategy by the Companies
- 8.2 Product Launch
- 8.3 Partnerships/Collaborations/Agreements/Exhibitions
Chapter 9. Company Profiles
- 9.1 Bluebird Bio
- 9.1.1 Company Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Benchmarking
- 9.1.4 Recent Development
- 9.2 Celgene Corporation
- 9.2.1 Company Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Benchmarking
- 9.2.4 Recent Development
- 9.3 Gilead Sciences, Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Benchmarking
- 9.3.4 Recent Development
- 9.4 Cellectis
- 9.4.1 Company Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Benchmarking
- 9.4.4 Recent Development
- 9.5 Servier Laboratories
- 9.5.1 Company Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Benchmarking
- 9.5.4 Recent Development
- 9.6 Pfizer Inc.
- 9.6.1 Company Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Benchmarking
- 9.6.4 Recent Development
- 9.7 Merck KGaA
- 9.7.1 Company Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Benchmarking
- 9.7.4 Recent Development
- 9.8 Amgen Inc.
- 9.8.1 Company Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Benchmarking
- 9.8.4 Recent Development
- 9.9 Intellia Therapeutics
- 9.9.1 Company Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Benchmarking
- 9.9.4 Recent Development
- 9.10 Novartis International AG
- 9.10.1 Company Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Benchmarking
- 9.10.4 Recent Development
- 9.11 Caribou Biosciences, Inc
- 9.11.1 Company Overview
- 9.11.2 Financial Performance
- 9.11.3 Product Benchmarking
- 9.11.4 Recent Development
- 9.12 Celyad
- 9.12.1 Company Overview
- 9.12.2 Financial Performance
- 9.12.3 Product Benchmarking
- 9.12.4 Recent Development
- 9.13 Bellicum Pharmaceuticals, Inc.
- 9.13.1 Company Overview
- 9.13.2 Financial Performance
- 9.13.3 Product Benchmarking
- 9.13.4 Recent Development
- 9.14 Noile-Immune Biotech
- 9.14.1 Company Overview
- 9.14.2 Product Benchmarking
- 9.14.3 Recent Development
- 9.15 Nanjing Legend Biotechnology Co., Ltd.
- 9.15.1 Company Overview
- 9.15.2 Product Benchmarking
- 9.15.3 Recent Development
- 9.16 Johnson & Johnson
- 9.16.1 Company Overview
- 9.16.2 Financial Performance
- 9.16.3 Product Benchmarking
- 9.16.4 Recent Development
- 9.17 Sangamo Therapeutics, Inc.
- 9.17.1 Company Overview
- 9.17.2 Financial Performance
- 9.17.3 Product Benchmarking
- 9.17.4 Recent Development
List of Tables
Table 1 Selected significant catalysts in CAR-T
Table 2 Various antigen targets are investigated for solid tumors
Table 3 Top Developers in CAR T cell clinical trials (September 2019)
Table 4 Catalyst for Small Players
Table 5 Selected deals and partnerships
Table 6 Cost of production (Lentivirus), 2022, (USD Billion)
Table 7 Cost of production (Plasmid), 2022, (USD Billion)
Table 8 Reimbursement amounts for CAR-T therapies per region, 2022, (USD Billion)
Table 9 Global CAR-T Cell Therapy Market, by Indication, 2020-2034, (USD Billion)
Table 10 Global CAR-T Cell Therapy Market, by DLBCL, 2020-2034, (USD Billion)
Table 11 Global CAR-T Cell Therapy Market, by ALL, 2020-2034, (USD Billion)
Table 12 Global CAR-T Cell Therapy Market, by CLL, 2020-2034, (USD Billion)
Table 13 Global CAR-T Cell Therapy Market, by MM, 2020-2034, (USD Billion)
Table 14 Global CAR-T Cell Therapy Market, by FL, 2020-2034, (USD Billion)
Table 15 Global CAR-T Cell Therapy Market, by Mastozytosis, 2020-2034, (USD Billion)
Table 16 Global CAR-T Cell Therapy Market, by Myeloid Fibrosis, 2020-2034, (USD Billion)
Table 17 Global CAR-T Cell Therapy Market, by MLL, 2020-2034, (USD Billion)
Table 18 Global CAR-T Cell Therapy Market, by Thymic Cancer, 2020-2034, (USD Billion)
Table 19 Global CAR-T Cell Therapy Market, by Glioblastoma, 2020-2034, (USD Billion)
Table 20 Global CAR-T Cell Therapy Market, by AML, 2020-2034, (USD Billion)
Table 21 Global CAR-T Cell Therapy Market, by Other Indications, 2020-2034, (USD Billion)
Table 22 Global CAR-T Cell Therapy Market, By Target Antigen, 2015 - 2026 (USD Billion)
- Table 23 Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2020-2034, (USD Billion)
- Table 24 Global CAR-T Cell Therapy Market, by BCMA, 2020-2034, (USD Billion)
- Table 25 Global CAR-T Cell Therapy Market, by Others, 2020-2034, (USD Billion)
Table 26 CAR-T Cell Therapy Market Assessment, By Geography, 2020-2034, (USD Billion)
Table 27 North America: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 28 North America: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 29 U.S.: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 30 U.S.: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 31 Canada: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 32 Canada: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 33 Europe: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 34 Europe: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 35 Germany: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 36 Germany: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 37 UK: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 38 UK: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 39 France: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 40 France: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 41 Italy: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 42 Italy: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 43 Spain: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 44 Spain: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 45 Netherlands: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 46 Netherlands: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 47 Austria: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 48 Austria: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 49 Asia Pacific: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 50 Asia Pacific: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 51 China: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 52 China: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 53 India: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 54 India: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 55 Japan: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 56 Japan: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 57 South Korea: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 58 South Korea: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 59 Australia: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 60 Australia: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 61 Latin America: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 62 Latin America: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 63 Brazil: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 64 Brazil: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 65 Mexico: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 66 Mexico: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 67 Middle East & Africa: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 68 Middle East & Africa: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 69 Saudi Arabia: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 70 Saudi Arabia: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
Table 71 UAE: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)
Table 72 UAE: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)
- List of Figures
- Figure 1. Market Highlights
- Figure 2. Research Methodology: Top Down & Bottom Up Approach
- Figure 3. Porter's Five Forces
- Figure 4. CAR-T Timelines
- Figure 5. CAR-T manufacturing process of Kymriah (Novartis)
- Figure 6. Market by Indication
- Figure 7. Market by Target Antigen
